Floatz logo

5-ala

Actinic Keratoses

Brigham and Women's HospitalSmall moleculePhase 2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
35/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Actinic Keratoses cohort.

Asset / SponsorPhaseRating
INGENOL MEBUTATE
University of California, San Francisco
Phase 4BB
FLUOROURACILUM
Sol-Gel Technologies, Ltd.
Phase 3BB
Efudex
Sol-Gel Technologies, Ltd.
Phase 3BB
Liposomal T4N5 Lotion
National Cancer Institute (NCI)
Phase 2B
Levulan® Kerastick®
Medical Dermatology Specialists
Phase 1/2CCC
5-ala
Brigham and Women's Hospital
N/AD

Same molecule, other indications

5-ala is also rated in:

brain neoplasmDormant
B
Indicative ·
61 / 100
View asset →
lentigo maligna melanomaDormant
B
Indicative ·
60 / 100
View asset →
glioblastomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →